Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 1:27 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 3,276 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Pfizer Clear all
Completed Phase 3 Interventional Results available

A Comparative Study Between PF-06410293 and Humira® in Combination With Methotrexate in Participants With Active Rheumatoid Arthritis

NCT04230213
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
PF-06410293, adalimumab
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Bowling Green, Kentucky • Duncansville, Pennsylvania • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Relative Bioavailability Study of Nirmatrelvir/Ritonavir 4 Different Fixed Dose Combination Tablets Relative to the Commercial Tablets in Healthy Participants

NCT05525910
View directory record Official record
Conditions
Biological Availability, Healthy Participants
Interventions
Nirmatrelvir/ ritonavir
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Learn About How Different Forms of the Study Medicine Called Ritlecitinib Pass the Intestines of Healthy Male Adults When Taken With or Without Food

NCT06369454
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Ritlecitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Aug 28, 2024 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Headache Ear Auditory Dizziness Sinus (HEADS) Registry

NCT07754266
View directory record Official record
Conditions
Headache Disorders, Dizziness, Vestibular Diseases, Sinus Disease, Vestibular Disorder, Migraine Disorders, Headache, Migraine, Facial Pain
Interventions
Not listed
Lead sponsor
Association of Migraine Disorders
Other
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2033
U.S. locations
1
States / cities
North Kingstown, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Depo-Provera: Bone Mineral Density and Total Body Calcium in Adolescent DP150CI Users and Non-Hormonal Contraception

NCT00139685
View directory record Official record
Conditions
Contraception, Bone Density
Interventions
Depo-Provera Contraceptive Injection - DP150CI
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years to 18 Years · Female only
Enrollment
350 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1998 – 2007
U.S. locations
12
States / cities
Los Angeles, California • Palo Alto, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2008 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Study Evaluating Desvenlafaxine Succinate Sustained Release (DVS SR) vs. Escitalopram in Postmenopausal Women

NCT00406640
View directory record Official record
Conditions
Depression, Depressive Disorder, Depressive Disorder, Major
Interventions
Desvenlafaxine succinate sustained-release (DVS SR), Escitalopram
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
40 Years to 70 Years · Female only
Enrollment
595 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
52
States / cities
Peoria, Arizona • Pasadena, California • San Diego, California + 46 more
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Irinotecan, Oxaliplatin, and Capecitabine as First-Line Therapy in Treating Patients With Metastatic or Unresectable Locally Advanced Small Bowel Cancer

NCT00433550
View directory record Official record
Conditions
Small Intestine Adenocarcinoma, Recurrent Small Intestine Cancer
Interventions
capecitabine, irinotecan hydrochloride, oxaliplatin
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
115
States / cities
Hartford, Connecticut • Boise, Idaho • Cedar Rapids, Iowa + 76 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2017 · Synced Oct 27, 2026, 1:27 PM EDT
Recruiting Phase 2 Interventional

A Study to Learn About Ritlecitinib for the Potential Treatment of Chronic Spontaneous Urticaria in Adults.

NCT07219615
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
Ritlecitinib 50 mg, Ritlecitinib 100 mg, Placebo - 50 mg, Placebo - 100 mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
19
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Bakersfield, California + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Combining Varenicline and Bupropion for Smoking Cessation

NCT00943618
View directory record Official record
Conditions
Smoking Cessation
Interventions
Varenicline, Bupropion, Placebo, Counseling/Phone Calls
Drug · Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
25 Years to 70 Years
Enrollment
641 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 4, 2025 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Not applicable Interventional Results available

Dexmedetomidine Versus Midazolam for Facilitating Extubation

NCT00744380
View directory record Official record
Conditions
Critical Illness
Interventions
Midazolam, Dexmedetomidine
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 85 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 28, 2016 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

NCT02091960
View directory record Official record
Conditions
HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions
Enzalutamide, Trastuzumab
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2024
U.S. locations
16
States / cities
Anaheim, California • Los Angeles, California • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 27, 2026, 1:27 PM EDT
Terminated Phase 3 Interventional Results available

Study Providing Monotherapy (Sitaxsentan) And Combination Therapy (Sitaxsentan+Sildenafil) To Subjects With Pulmonary Arterial Hypertension (PAH) To Assess Long-Term Safety

NCT00796510
View directory record Official record
Conditions
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Interventions
Sitaxsentan, Sitaxsentan and Sildenafil
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years to 80 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Fountain Valley, California
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).

NCT00413010
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
pregabalin, placebo
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
18 Years and older
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
35
States / cities
Arcadia, California • Burbank, California • Redlands, California + 28 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

A STUDY OF A RSV VACCINE WHEN GIVEN TOGETHER WITH TDAP IN HEALTHY NONPREGNANT WOMEN AGED BETWEEN 18 TO 49 YEARS

NCT04071158
View directory record Official record
Conditions
Respiratory Tract Infection
Interventions
RSV Vaccine, Tdap, Placebo
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 49 Years · Female only
Enrollment
713 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
16
States / cities
Stockbridge, Georgia • Honolulu, Hawaii • Wichita, Kansas + 12 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2021 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 3 Interventional Results available

A Phase 3 Study Comparing 2 Doses Of CP-690,550 And The Active Comparator, Humira (Adalimumab) Vs. Placebo For Treatment Of Rheumatoid Arthritis

NCT00853385
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
CP-690,550, Placebo, Biologic TNFi
Drug · Other · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
717 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
38
States / cities
Gilbert, Arizona • Glendale, Arizona • Mesa, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Jan 18, 2013 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Efficacy And Safety Of Sunitinib In Women With Advanced Breast Cancer

NCT00471276
View directory record Official record
Conditions
Breast Neoplasms
Interventions
sunitinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
31
States / cities
Bakersfield, California • Burbank, California • Fountain Valley, California + 24 more
Source: ClinicalTrials.gov public record
Updated Jul 25, 2011 · Synced Oct 27, 2026, 1:27 PM EDT
Terminated Phase 2 Interventional

Safety and Efficacy Study of PF-06835375 in Primary Immune Thrombocytopenia

NCT05070845
View directory record Official record
Conditions
Primary Immune Thrombocytopenia
Interventions
PF-06835375
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Greenville, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Not applicable Interventional

Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder

NCT00715039
View directory record Official record
Conditions
Anxiety Disorders
Interventions
lorazepam, placebo, paroxetine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
15
States / cities
Glendale, California • Northridge, California • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2008 · Synced Oct 27, 2026, 1:27 PM EDT
Terminated Phase 4 Interventional Results available

Kaletra and Maraviroc in Antiretroviral Therapy (ART)-Naive Patients (KALMAR Study)

NCT01068873
View directory record Official record
Conditions
HIV Infections
Interventions
lopinavir/ritonavir plus maraviroc
Drug
Lead sponsor
Temple University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 2, 2020 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance

NCT02799745
View directory record Official record
Conditions
Prostate Cancer
Interventions
Enzalutamide, Active Surveillance
Drug · Other
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
18 Years and older · Male only
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
50
States / cities
Birmingham, Alabama • Homewood, Alabama • Tucson, Arizona + 41 more
Source: ClinicalTrials.gov public record
Updated Dec 6, 2024 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate

NCT00628095
View directory record Official record
Conditions
Arthritis, Rheumatoid
Interventions
CE-224,535, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 99 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
14
States / cities
Mesa, Arizona • DeBary, Florida • Lake Mary, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 27, 2026, 1:27 PM EDT
Active, not recruiting No phase listed Observational

Effectiveness of ABRYSVO® Maternal Respiratory Syncytial Virus (RSV) Vaccine Against RSV in Infants in Western Pennsylvania

NCT06813872
View directory record Official record
Conditions
Respiratory Syncytial Viruses
Interventions
ABRYSVO Vaccination
Biological
Lead sponsor
Pfizer
Industry
Eligibility
0 Months to 6 Months
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 3, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Completed No phase listed Observational

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

NCT06393465
View directory record Official record
Conditions
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Interventions
Tafamidis
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 27, 2026, 1:27 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Rimegepant and Placebo for Pain in IBS

NCT06221111
View directory record Official record
Conditions
Irritable Bowel Syndrome
Interventions
Rimegepant 75 MG [Nurtec]
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 70 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 27, 2026, 1:27 PM EDT